Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 3/20 | 0.46 |
| ▸ | PRKCQ | Q04759 | 16/20 | 0.45 |
| ▸ | PRKCD | Q05655 | 12/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7096071 | 0.76 | IMPDH2 (0.49) | PIK3CDPRKCQPRKCDPIK3CBPIK3CG | |
| SCHEMBL29709559 | 0.76 | PIK3CD (0.44) | PIK3CDPIK3CBPIK3CGDHFR | |
| SCHEMBL3726444 | 0.74 | PRKCQ (0.46) | PIK3CDPRKCQPRKCD | |
| SCHEMBL2979788 | 0.74 | PRKCQ (0.77) | PRKCQPRKCD | |
| SCHEMBL1146448 | 0.73 | PRKCQ (0.60) | PRKCQPRKCD | |
| SCHEMBL3073584 | 0.73 | ATR (0.47) | PIK3CDPRKCQPRKCDPIK3CBPIK3CG | |
| SCHEMBL3304532 | 0.73 | PIK3CD (0.44) | PIK3CDPIK3CBPIK3CGDHFR | |
| SCHEMBL20540332 | 0.72 | PIK3CD (0.64) | PIK3CDPIK3CBPIK3CGDHFR | |
| SCHEMBL29709511 | 0.71 | ASH1L (0.50) | PIK3CDPRKCQPRKCDPIK3CBPIK3CG | |
| SCHEMBL2126661 | 0.71 | PRKCQ (0.43) | PRKCQPRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781591-B2 | Substituted 3-cyanopyridines as protein kinase inhibitors | WYETH LLC (US) | 2010-08-24 | — | — | US | disclosed |
| US-20070287708-A1 | Substituted 3-cyanopyridines as protein kinase inhibitors | WYETH LLC | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287708-A1 | Substituted 3-cyanopyridines as protein kinase inhibitors | CNKSR1, MAP3K1, MAP3K7 | PIK3CD 674/4885PRKCQ 165/4885PRKCD 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.